| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
88,430,000 |
| Market
Cap: |
313.04(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.5 - $8.26 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Caribou Biosciences is a clinical-stage genome-editing biopharmaceutical company focused on developing transformative Clustered Regularly Interspaced Short Palindromic Repeats therapies for patients with devastating diseases. Co.'s primary product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 chimeric antigen receptor (CAR)-T cell therapy with programmed cell death protein 1 removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. CB-012 is Co.'s allogeneic armored CAR-T cell product candidate targeting CD371, which is in preclinical development for the treatment of relapsed or refractory acute myeloid leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
58,875 |
| Total Sell Value |
$0 |
$0 |
$0 |
$628,685 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
3 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fischesser Ryan |
VP of Finance and Controller |
• – – |
2022-01-11 |
4 |
B |
$2.69 |
$29,553 |
D/D |
7,387 |
109,082 |
2.74 |
-36% |
|
| Fischesser Ryan |
VP of Finance and Controller |
• – – |
2021-12-20 |
4 |
B |
$2.69 |
$3,056 |
D/D |
1,136 |
101,695 |
2.66 |
-50% |
|
| Mcclung Barbara G |
Chief Legal Officer |
• – – |
2021-12-07 |
4 |
B |
$2.69 |
$16,482 |
D/D |
6,127 |
348,971 |
2.74 |
-56% |
|
| Mcclung Barbara G |
Chief Legal Officer |
• – – |
2021-10-20 |
4 |
B |
$2.69 |
$24,799 |
D/D |
9,219 |
342,844 |
2.74 |
-56% |
|
| Kanner Steven |
Chief Scientific Officer |
• – – |
2021-10-12 |
4 |
B |
$1.81 |
$220,757 |
D/D |
114,860 |
215,031 |
2.74 |
-55% |
|
| Fischesser Ryan |
VP of Finance and Controller |
• – – |
2021-10-11 |
4 |
B |
$2.69 |
$4,697 |
D/D |
1,746 |
100,559 |
2.66 |
-50% |
|
| Fmr Corp |
See Remark 1 |
– – – |
2021-07-27 |
4 |
A |
$0.00 |
$0 |
I/I |
3,323,284 |
1,464,775 |
|
- |
|
32 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.11 (3.01%) 
